ArticleCardiovascular therapeutics2025
Impact of Dronedarone on Early Recurrence After Catheter Ablation in Patients With Nonparoxysmal Atrial Fibrillation.
Article in Cardiovascular therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study is aimed at comparing the efficacy and safety of dronedarone, amiodarone, and propafenone in preventing early recurrence of atrial arrhythmias during the blanking period following catheter ablation in patients with nonparoxysmal atrial fibrillation. Methods: We retrospectively analyzed 408 patients with nonparoxysmal atrial fibrillation who underwent their first catheter ablation. Patients were divided into three groups based on the postoperative antiarrhythmic drug prescribed: dronedarone, amiodarone, or propafenone. A propensity score matching (PSM) analysis was performed as the primary analysis to compare early recurrence rates and drug-related adverse events. An inverse probability of treatment weighting (IPW) analysis was conducted as a sensitivity analysis. Results: Of the 408 patients, 65 (15.9%) experienced early recurrence. The early recurrence rate was significantly lower in the dronedarone group (9.2%) compared to propafenone (27.2%), but not significantly different from amiodarone (14.0%). The dronedarone group showed a lower recurrence rate of atrial flutter compared to both the propafenone and amiodarone groups ( Conclusion: In this retrospective study of patients with nonparoxysmal atrial fibrillation after catheter ablation, dronedarone and amiodarone showed a trend toward better efficacy than propafenone in preventing overall early recurrence. Dronedarone demonstrated a specific advantage in preventing early recurrence of atrial flutter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.